Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells

MLA

Juha R. Savinainen, et al. “Evaluation of FASN Inhibitors by a Versatile Toolkit Reveals Differences in Pharmacology between Human and Rodent FASN Preparations and in Antiproliferative Efficacy in Vitro vs. in Situ in Human Cancer Cells.” European Journal of Pharmaceutical Sciences, vol. 149, June 2020, p. 105321. EBSCOhost, https://doi.org/10.1016/j.ejps.2020.105321.

APA

Juha R. Savinainen, Tapio Nevalainen, Prosanta K. Singha, Antti Poso, Arun Kumar Tonduru, Mahadeo R. Patil, Tuomo Laitinen, Kiira Mäklin, Taina Vihavainen, & Jarmo T. Laitinen. (2020). Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells. European Journal of Pharmaceutical Sciences, 149, 105321. https://doi.org/10.1016/j.ejps.2020.105321

Chicago

Juha R. Savinainen, Tapio Nevalainen, Prosanta K. Singha, Antti Poso, Arun Kumar Tonduru, Mahadeo R. Patil, Tuomo Laitinen, Kiira Mäklin, Taina Vihavainen, and Jarmo T. Laitinen. 2020. “Evaluation of FASN Inhibitors by a Versatile Toolkit Reveals Differences in Pharmacology between Human and Rodent FASN Preparations and in Antiproliferative Efficacy in Vitro vs. in Situ in Human Cancer Cells.” European Journal of Pharmaceutical Sciences 149 (June): 105321. doi:10.1016/j.ejps.2020.105321.